PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
De-Colle, C.* ; Menegakis, A.* ; Mönnich, D.* ; Welz, S.* ; Boeke, S.* ; Sipos, B.* ; Fend, F.* ; Mauz, P.S.* ; Tinhofer, I.* ; Budach, V.* ; Abu Jawad, J.* ; Stuschke, M.* ; Balermpas, P.* ; Rödel, C.* ; Grosu, A.-L.* ; Abdollahi, A.* ; Debus, J.* ; Belka, C.* ; Ganswindt, U.* ; Pigorsch, S.U. ; Combs, S.E. ; Lohaus, F.* ; Linge, A.* ; Krause, M.* ; Baumann, M.* ; Zips, D.*

SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.

Radiother. Oncol. 126, 125-131 (2018)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Introduction: Preclinical and clinical data suggest that the chemokine pathway governed by SDF-1 and CXCR4 contributes to a resistant phenotype. This retrospective biomarker study aims to explore the specific prognostic value of SDF-1 and CXCR4 expression in locally advanced head and neck squamous cell carcinomas (HNSCC) treated with primary radiochemotherapy (RT-CT). Material and methods: Biopsies from 141 HNSCC tumours of the oral cavity, oropharynx and hypopharynx were evaluated for SDF-1 and CXCR4 expression by immunofluorescence. SDF-1 and CXCR4 expression was correlated with clinico-pathological characteristics and outcome after RT-CT. Results: Patients with tumours exhibiting overexpression of intracellular SDF-1 and CXCR4 have a higher risk for loco-regional relapse and a worse overall survival after RT-CT (multivariate analysis, hazard ratio 2.33, CI [1.18-4.62], p = 0.02 and hazard ratio 2.02, CI [1.13-3.59], p = 0.02, respectively). Similar results were observed when only the subgroup of HPV DNA negative patients were analysed (hazard ratio 2.23 and 2.16, p = 0.02 and p = 0.01, respectively). Conclusions: Our data support the importance of SDF-1 and CXCR4 expression for loco-regional control and overall survival in HNSCC after primary radiochemotherapy. Prospective multivariate validation and further studies into CXCR4 inhibition to overcome radiation resistance are warranted. (C) 2017 Elsevier B.V. All rights reserved.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.942
1.612
14
12
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Sdf-1 ; Cxcr4 ; Head And Neck Cancer ; Prognostic ; Biomarker ; Primary Radiochemotherapy; Squamous-cell Carcinoma; Chemokine Receptor Cxcr4; Group Dktk-rog; Human Nasopharyngeal Carcinoma; Lymph-node Metastasis; Radiation Oncology; Postoperative Radiochemotherapy; Mesenchymal Transition; Factor-1/cxcr4 System; Marker Expression
Sprache englisch
Veröffentlichungsjahr 2018
Prepublished im Jahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 0167-8140
e-ISSN 1879-0887
Zeitschrift Radiotherapy and Oncology
Quellenangaben Band: 126, Heft: 1, Seiten: 125-131 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Clare
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
DOI 10.1016/j.radonc.2017.10.008
WOS ID WOS:000425578100016
Scopus ID 85031709751
PubMed ID 29061496
Erfassungsdatum 2017-11-08
[➜Korrektur melden]